P/E at 37.01 vs Industry's 36.91: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Premium Reflects Sector Alignment

Sun Pharmaceutical Industries Ltd trades at a P/E of 37.01, just above the Pharmaceuticals & Biotechnology industry average of 36.91. This near-parity suggests that the market values the company in line with its peers, reflecting neither a significant premium nor discount. The marginal premium could be attributed to the company’s large-cap status and its consistent earnings growth over recent years. However, this valuation does not imply an excessive stretch relative to the sector, which has seen mixed results recently — 7 stocks positive, 5 flat, and 1 negative among 13 reporting so far. Investors might wonder previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Strong Long-Term Gains Amid Short-Term Volatility

The stock’s performance over the past year has been robust, delivering a 22.27% gain compared to the Sensex’s 2.27% loss. This outperformance extends over longer horizons as well, with three-year returns at 71.15% versus the Sensex’s 19.77%, and five-year returns at 148.24% compared to 45.02% for the benchmark. However, the ten-year return of 131.38% trails the Sensex’s 180.33%, indicating some relative underperformance over the longest timeframe.

In contrast, the short-term momentum reveals a more cautious picture. The stock has declined by 1.08% over the last two days, underperforming the sector by 0.83% today and falling 2.89% over the past week while the Sensex gained 1.01%. The one-month and three-month returns remain positive at 1.88% and 5.33% respectively, but the recent dip suggests some profit-taking or consolidation. This divergence between strong medium-to-long-term gains and recent softness raises the question is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Mixed Signals from Technical Indicators

The technical setup for Sun Pharmaceutical Industries Ltd is somewhat mixed. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, signalling a generally positive medium-to-long-term trend. However, it remains below the 5-day and 20-day moving averages, indicating short-term weakness or a pause in momentum. This configuration often suggests a recent pullback within an overall uptrend, which aligns with the recent two-day consecutive fall and weekly underperformance. The 5-day and 20-day averages act as immediate resistance levels, and the stock’s ability to reclaim these could determine the near-term direction.

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed Results

The Pharmaceuticals & Biotechnology sector has delivered a mixed bag of results in the recent reporting season. Out of 13 stocks that declared results, 7 posted positive outcomes, 5 remained flat, and 1 reported negative results. This uneven performance reflects ongoing challenges and opportunities within the sector, including regulatory pressures, pricing dynamics, and innovation cycles. Against this backdrop, Sun Pharmaceutical Industries Ltd’s steady valuation and strong long-term returns stand out, though the recent short-term softness aligns with sector-wide volatility. Investors might consider should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Hold. The rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. While the current rating is not disclosed, the data-driven approach considers the company’s premium valuation relative to the sector, its strong medium-to-long-term performance, and the recent technical signals. This comprehensive analysis provides a nuanced view of the stock’s position within the Pharmaceuticals & Biotechnology sector and the broader market.

Conclusion: A Balanced Valuation with Divergent Momentum Signals

The data for Sun Pharmaceutical Industries Ltd reveals a stock trading at a valuation closely aligned with its sector peers, supported by strong medium-to-long-term returns that significantly outperform the Sensex. However, recent short-term weakness and a mixed moving average configuration suggest caution in the near term. The Pharmaceuticals & Biotechnology sector’s mixed results further underscore the complexity of the environment in which the company operates. Taken together, these factors highlight the importance of analysing multiple timeframes and metrics when assessing the stock’s prospects — what is the current rating for Sun Pharmaceutical Industries Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today